Study results that show Samsung Bioepis’s Soliris biosimilar is bioequivalent to the original drug have been presented.

On the 13th, the company announced that its biosimilar, SB12 has demonstrated equal effect to its original drug Soliris at the American Society of Hematology (ASH) Annual Meeting that is being held in New Orleans.

Soliris is a rare disease treatment used to treat incurable rare diseases like paroxysmal nocturnal hemoglobinuria (PNH) that was developed by the US pharmaceutical company Alexion. SB12 is a biopharmaceutical drug developed using the same active ingredient contained in Soliris, eculizumab.

Samsung Bioepis presented statistical analysis resu